83: Late Toxicity after TBI in AHCT for Relapsed Follicular Lymphoma

Tisseverasinghe, Steven; Samant, Rajiv; Sabloff, Mitchell; Xu, Yuhui; Bredeson, Christopher; Huebsch, Lothar; Genest, P.

doi:10.1016/s0167-8140(16)33482-x

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the subacute setting, TBI can lead to radiation pneumonitis and sinusoidal obstruction syndrome both of which appear to be dropping in incidence with improvements in TBI delivery, dose fractionation, reduction in lung doses and better supportive care measures [60,[66][67][68][69].…”

Section: Tbi Toxicitiesmentioning

confidence: 99%

Screening for Breast Cancer in 2018—What Should We be Doing Today?

2018

View full text Add to dashboard Cite

Although screening mammography has delivered many benefits since its introduction in Canada in 1988, questions about perceived harms warrant an up-to-date review. To help oncologists and physicians provide optimal patient recommendations, the literature was reviewed to find the latest guidelines for screening mammography, including benefits and perceived harms of overdiagnosis, false positives, false negatives, and technologic advances. For women 40-74 years of age who actually participate in screening every 1-2 years, breast cancer mortality is reduced by 40%. With appropriate corrections, overdiagnosis accounts for 10% or fewer breast cancers. False positives occur in about 10% of screened women, 80% of which are resolved with additional imaging, and 10%, with breast biopsy. An important limitation of screening is the false negatives (15%-20%). The technologic advances of digital breast tomosynthesis, breast ultrasonography, and magnetic resonance imaging counter the false negatives of screening mammography, particularly in women with dense breast tissue.

show abstract

Section: Tbi Toxicitiesmentioning

confidence: 99%

Screening for Breast Cancer in 2018—What Should We be Doing Today?

2018

View full text Add to dashboard Cite

show abstract

Section: Tbi Toxicitiesmentioning

confidence: 99%

Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on?

Sabloff

Tisseverasinghe²,

Babadağli

et al. 2021

Current Oncology

Self Cite

View full text Add to dashboard Cite

Total body irradiation (TBI), used as part of the conditioning regimen prior to allogeneic and autologous hematopoietic cell transplantation, is the delivery of a relatively homogeneous dose of radiation to the entire body. TBI has a dual role, being cytotoxic and immunosuppressive. This allows it to eliminate disease and create “space” in the marrow while also impairing the immune system from rejecting the foreign donor cells being transplanted. Advantages that TBI may have over chemotherapy alone are that it may achieve greater tumour cytotoxicity and better tissue penetration than chemotherapy as its delivery is independent of vascular supply and physiologic barriers such as renal and hepatic function. Therefore, the so-called “sanctuary” sites such as the central nervous system (CNS), testes, and orbits or other sites with limited blood supply are not off-limits to radiation. Nevertheless, TBI is hampered by challenging logistics of administration, coordination between hematology and radiation oncology departments, increased rates of acute treatment-related morbidity and mortality along with late toxicity to other tissues. Newer technologies and a better understanding of the biology and physics of TBI has allowed the field to develop novel delivery systems which may help to deliver radiation more safely while maintaining its efficacy. However, continued research and collaboration are needed to determine the best approaches for the use of TBI in the future.

show abstract